JCB logo
amgmicro.com
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 7 September 2004. doi:10.1083/jcb1666rr4
The Rockefeller University Press, 0021-9525 $8.00
JCB, Volume 166, Number 6, 763-763
This Article
Right arrow Full Text (PDF, 851K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wells, W. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wells, W. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Research Roundup

Slow but steady wins the drug race



A slow-growing variant cell (arrow) can escape ampicillin (present at 6:50).

Balaban/AAAS

Bacteria that survive antibiotic assaults fall into two groups: resistant mutants; and the more mysterious persistent cells. Persisters, a known entity since 1944, survive the intial burst of antibiotics but unlike mutants may succumb to later treatments. Nathalie Balaban (now at Hebrew University, Jerusalem, Israel), Stanislas Leibler (Rockefeller University, New York, NY), and colleagues now find that persisters are a constant presence in the population—a slow-growing minority that acts as a reserve population in case of chemical attack.

The alternative explanations for persisters are legion. They might be completely dormant, or normal cells caught in a protected part of the cell cycle when the antibiotic arrives, or a state induced in response to antibiotic treatment. Balaban and colleagues looked at the behavior of single cells immobilized in a microfluidic device and saw that the few cells surviving antibiotic treatment were growing slowly even before the drug was added.

Extrapolating from the behavior of two mutants that produce an excess of persisters, the team deduced that wild-type cells make persisters both in response to time spent in stationary phase and at a constant rate during normal growth. Persisters escape their sluggish state at a slow but appreciable rate.

For basic researchers, the persistence pathway offers a bacterial example of an alternative phenotypic state, and one that is somehow generated at a low, constant frequency. For clinicians,the pathway may present a target for drugs that would get rid of the few bacteria left after conventional antibiotic treatments. {blacksquare}

Reference:

Balaban, N., et al. 2004. Science. doi: 10.1126/science.1099390.[Abstract/Free Full Text]



William A. Wells

wellsw{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF, 851K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wells, W. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wells, W. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents